Notably, a robust synergistic antileukemic effect was observed with the combination of ponatinib and asciminib in CML-BC cell lines and CML-BC stem cells carrying the BCR::ABL1 T315I mutation [10]. The gene discussed is BCR; the disease is breast cancer.